PB
Paradigm Biopharmaceuticals Limited
PBIGF · OTC
$0.18 -3.16% (-$0.01)
1M +84.00%
Market Cap $159.0M
P/E Ratio -
Div. Yield -
ROE 347.77%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 45.89x
P/S 1,987.14x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 59.88%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 76,248.10%
Gross margin 102.77%
FCF margin 54,507.20%
Quality
0 /100
Poor ROA 184.36%
ROIC 484.07%
Asset turnover 0.00x
Debt
17 /100
High Int. coverage -24.83x
Debt/Equity 2.16x
Current ratio 1.10x
Stability
19 /100
Unstable Profitable years 0
Beta -0.02x
EPS volatility 121.06%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PBIGF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul John Rennie
Employees
8
Headquarters
Melbourne
Nadcházející události
24 ÚNO
Earnings
Upcoming earnings report